BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Positive 54.9%

Neg 0% Neu 0% Pos 54.9%

BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $46.